GBS patients presented with significantly more day 7 plasma cells (31.2 ± 16.1% among CD19+ B cells, n = 40), compared with other autoimmune patients (CIDP; 20.1 ± 15.4%, n = 14, p = 0.0092, MG; 8.3 ± 2.9%, n = 7, p<0.0001, IM; 5.3 ± 2.7%, n = 6, p<0.0001; Figure 2C left panel). This evidence concerns the gene CD19 and Guillain-Barre syndrome.